Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations.
"Tiffany comes to Cerulean with deep experience and demonstrated leadership in clinical development and operations that will be crucial in supporting our clinical development of CRLX101 and CRLX301," said Paul Friedman, MD, Executive Chairman of Cerulean.